ESG Report 2022

Annual Research Results As of 31 December 2022, the Group has a total of enhance the Group's operational and production 29 generic and new drug projects under efficiency. development, including 14 chemical drugs and 15 biologics, of which 6 are in the clinical stage, 2 are in pending stage for clinical approval and 21 are in the pre-clinical stage. In addition, the Group has actively responded to the national requirements for consistency evaluation on the quality and efficacy of generic drugs, with 11 products already been approved for consistency evaluation and another 15 products in progress. The Group has a number of key projects under research and their indications and development stages are as shown above (Products in R&D), which are expected to provide a good foundation for the sustainable development of the Group's operations in the future. In addition, with the Group's excellent product quality, production processes, and production facilities, and the Group actively seeking breakthroughs to create benefits, we have achieved several research successes. These successes not only provide more quality pharmaceutical products to the public, but also R&D of Diabetes Drugs Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes. Semaglutide is the most effective blood-glucose-reduction GLP-1 analogue among the same target drugs existing in the market. It only requires to be injected once a week, and is characterized by safety, simplicity and significant efficacy. By promoting the secretion of insulin by pancreatic cells, it can significantly reduce the blood glucose in vivo, reduce the weight of the patients and show obvious cardiovascular benefits. In addition to the indication of type diabetes, several indications including weight loss, non-alcoholic steatohepatitis (NASH) and Alzheimer's disease are currently under research. ll Insulin Degludec and Insulin Aspart injection is a new-generation ultra-long-acting combination of basal insulin analogue and mealtime insulin analogue, containing 70% insulin Degludec and 30% insulin Aspart. The two components are soluble independently and reliably, without changes of their respective pharmacological properties, and work together to control the fasting blood glucose and the postprandial blood glucose. Compared with the premixed insulin analogues applied clinically, insulin Degludec and Insulin Aspart injection demonstrates a better simulation of the secretion pattern of physiological insulin and delivers a safer and more effective treatment for reducing blood glucose, thus providing diabetes patients with a better option to comprehensively control blood glucose. Insulin Degludec and Insulin Aspart Injection Being Approved for Clinical Trials Semaglutide Injection Being Approved for Clinical Trials 14 Environmental, Social and Governance Report 2022 The United Laboratories International Holdings Limited